Latest on Gene Therapy and Stem Cell Therapy for Retinal Diseases

AAO 2017 Press Conference Nov. 13, 2017
Stephen R. Russell, M.D., University of Iowa Health Care
Irene Maumenee, M.D, 2017 Academy Laurate recipient
Ninel Z. Gregori, M.D., Bascom Palmer Eye Institute
Eyal Banin, M.D., Ph.D , Hadassah-Hebrew University
Medical Center in Jerusalem, Israel

Alzheimer's Embrel Treatment – The Latest Breakthrough in Treating Alzheimer's Disease

One of the most common types of diseases that occurs to adults is Alzheimer's disease. It is a kind of mental disorder that is also known as "Dementia". It is a brain disorder that affects the ability of the brain to process rational or normal thought that can inhibit the daily activities of the people suffering from this disorder. Basically, this disease can affect the part of the brain that is responsible for memory, thought and language.

Alzheimer's disease has been one of the leading causes of death in America. This disorder was first identified in 1907. It can affect the memory ability of the brain, making rational decisions, capacity of learning new things and new knowledge making the affected person incapable of doing anything. Basically, the hallmark of this kind of disease is the loss of memory. During the age of 65 or older, people with this disease can already experience the first episodes of forgetfulness, which is one of the symptoms of this disease.

This kind of disease is well-known of robbing the memories and personalities of the people that are suffering from this kind of disorder. Since this disease was discovered, a lot of people believed that nothing could be done to prevent this disease. They believed that it is a disease that people must look forward to when they reached adulthood. It is also said that this kind of disease can not be cured.

However, there is a certain treatment that can reverse the effects of Alzheimer's disease. It is known as the Alzheimer's Embrel perispinal injection treatment. This kind of treatment can improve and restore the memory of the patient and drastically reduce dementia, reversing the effects of Alzheimer's disease. However, only a few dozen people know how to manage this kind of treatment. Today, it is really hard to find doctors that can perform this life-changing treatment for people who are suffering from Alzheimer's disease.

This is where Neurological Wellness Center comes in. They are capable of providing Embrel presispinal injection training that will help family care givers to have knowledge on how to manage this Alzheimer's dementia therapy. They are allowing their clients to experience for themselves the improvements that can be provided by this therapy like improvements in memory, mood and cognitive function. The Neurological Wellness Center was established to make this breakthrough treatment possible for all the Americans who are looking for possible treatments for this serious disease.

The Latest Treatments For Alzheimer's Disease

Since Alzheimer's disease is commonly a slow process, the disease affects people differently and therefore individuals respond differently to different treatments. Currently, there is no drug or treatment program that stops the progress of Alzheimer's disease. However, for individuals who are in mild, and middle stages of the disease, certain drugs have proved successful.

The latest drugs for treating Alzheimer's disease

Aricept (donepezil)

Given orally, this medication is a reversible inhibitor of the enzyme acetylcholinesterase. It is used to treat symptoms in people with mild to moderate Alzheimer's disease. Our brains normally produce acetylcholine, a chemical thought to be important for learning and memory. People with Alzheimer's disease have lower brain levels of acetylcholine. Aricept acts by decreasing the activity of acetylcholinesterase, an enzyme whose function is to break down acetylcholine. It is believed that by reducing the breakdown of acetylcholine, it will lead to an increase in the level of acetylcholine in the brain.

Cognex (tacrine)

Given orally, this is another medication that inhibits the enzyme acetylcholinesterase. Tacrine will not cure Alzheimer's disease, and it will not stop the disease from getting worse. However, tacrine can improve thinking ability in some patients with Alzheimer's disease.

Exelon (rivastigmine)

Another cholinesterase inhibitor given orally. This medication is used to treat loss of memory and thinking ability associated with Alzheimer's Disease.

Razadyne (galantamine)

This medication was formerly known as Reminyl. It was changed to razadyne on July 1st 2005. Razadyne is a competitive acetylcholinesterase inhibitor. It has been shown to treat some of the symptoms of Alzheimer's disease successfully.

Namenda (memantine)

Approved by the FDA in October, 2003, this medication is given orally, and works differently from the acetylcholinesterase inhibitors. Glutamate is the main excitatory neurotransmitter in the brain. It it thought that too much glutamate in the brain can cause cellular damage. Namna works by blocking the effects of glutamate.

Antioxidants

Clinical trials have shown that vitamin E slows the progress of Alzheimer's disease by about seven months. Current clinical trials are underway to determine whether vitamin E will slow the progress of Alzheimer's disease.

Other clinical trials are underway to determine whether vitamin E and selenium supplements can help slow or prevent symptoms of Alzheimer's disease.

Ginkgo Biloba

The latest studies using Ginkgo Biloba extract from leaves has shown this chemical to be of some help with treating Alzheimer's disease symptoms. However, there is no evidence that Ginkgo Biloba but will cure or prevent Alzheimer's disease. Currently, there is some clinical evidence showing that Ginkgo Biloba can delay cognitive deficits or prevent dementia to a certain extent in older people.

Estrogen

Clinical trials have been conducted showing that estrogen therapy can protect the brain against damages caused by Alzheimer's disease. These studies were originally conducted using estrogen on women for hormone replacement therapy. Positive response regarding Alzheimer's disease prevention, was noted as a side effect. Current evidence has shown while estrogen therapy can help prevent the severity or symptoms of Alzheimer's disease, it will not slow the progress of Alzheimer's disease once it has already been diagnosed. Also, one study showed that women over the age of 65 who were receiving estrogen and progestin therapy, were at greater risk of dementia and greater risk of developing Alzheimer's disease symptoms.

Individuals may participate in current scientific clinical trials

People with Alzheimer's disease may participate in scientific clinical trials. In order to qualify to participate in the studies, certain tests must be conducted. For more information about participating in current clinical studies for the treatment of Alzheimer's disease, one can find out more information by calling 1-800-438-4380, which is the Alzheimer's Disease Treatment Center. The Alzheimer's Disease Treatment Centers are located throughout the United States.

The Alzheimer's Association

The Alzheimer's Association currently has programs and help available for caregivers and family members of people with Alzheimer's disease. For more information please contact the Alzheimer's Association.

Latest Insider Trade Update UnitedHealth Group Incorporated (UNH)

Interest in UnitedHealth Group Incorporated (NYSE:UNH) has gathered pace in recent weeks as a result of the underlying changes in the state of insider activity. On Oct. 4, 2017 UNH saw a modest increase, closing the day at $198.63, or a increase of $1.85 or (0.93%). Volume levels waned and UNH actually managed a declined which translated to 2.28 million shares changing hands on the day. UNH traded on a high for the day of 200.73 with a corresponding low of 198.43.The day’s high marked a slight increase on the previous day’s close which saw UNH finish the day’s trading at 198.43.

Driving interest in UnitedHealth Group Incorporated (UNH) is a number of factors, including perhaps, a steady increase of the profile of the company as insider activity takes center stage. This activity has been headed largely by William Ballard, a director of the company. William Ballard has seen steady activity on the buy side, and on October 2, 2017, executed an option to buy 222 shares. The purchase, resulted in William Ballard bringing total 71364 shares. Other officers which have joined William Ballard in buying shares include Richard Burke who bought for 222 shares. The option since executed brings Burke ownership to 1.83 million shares. Timothy Flynn, a director at (UNH), bought 380 shares to bring his total ownership in the stock to 1,181 shares.

Institutional investors have also been busy with the stock. Their activity in UNH in recent trading has also spurred interest in the stock. The most recent shifts in number of shares owned by institutions came on June 30, 2017 when Geode Capital Management, Llc sold 279 shares from its total ownership of 26608. The value for the sale was $23000. On the opposite side of that transaction from Geode Capital Management, Llc stood Vanguard Group Inc which added 3332 shares to its existing stake, bringing total stake held in UNH to 187898 shares. That transaction by Vanguard took place on June 30, 2017, the same day Susquehanna International Group, Llp purchased an additional 27696 shares in UNH to bring its total stake to 27696. Susquehanna’s stake was worth $24000 at the time of purchase. Institutional shareholders currently hold a 87.53% stake overall in UNH.

UnitedHealth Group Incorporated (NYSE:UNH) continues to be a formidable company. Current market cap is $194.08B and the stock has an EPS of $8.32. The P/E Ratio for UNH is 23.48. Over the course of the last year UNH has set a 52-week high of $200.76 while the corresponding low set was $133.03.

Latest Insider Trade Update About UnitedHealth Group Incorporated (UNH)

Interest in UnitedHealth Group Incorporated (NYSE:UNH) has gathered pace in recent weeks as a result of the underlying changes in the state of insider activity. On Sep. 27, 2017 UNH saw a modest increase, closing the day at $192.70, or a increase of $1.79 or (0.93%). Volume levels spiked and UNH actually managed a breakout which translated to 3.23 million shares changing hands on the day. UNH traded on a high for the day of 195.62 with a corresponding low of 191.74. The day’s high marked a slight increase on the previous day’s close which saw UNH finish the day’s trading at 191.74.

Driving interest in UnitedHealth Group Incorporated (UNH) is a number of factors, including perhaps, a steady increase of the profile of the company as insider activity takes center stage. This activity has been headed largely by Richard Burke, a director of the company. Richard Burke has seen steady activity on the buy side, and on September 25, 2017, executed an option to buy 6090 shares. The purchase, at a price of $47.9, resulted in Richard Burke bringing total 1.83 million shares. Other officers which have joined Richard Burke in buying shares include William Ballard who bought for 84 shares. The option since executed brings Ballard ownership to 71142 shares. Timothy Flynn, a director at (UNH), bought 4 shares to bring his total ownership in the stock to 801 shares.

But it’s not just buying activity that is creating investor interest in UNH; over the last several weeks, several insiders have sold shares.

Institutional investors have also been busy with the stock. Their activity in UNH in recent trading has also spurred interest in the stock. The most recent shifts in number of shares owned by institutions came on June 30, 2017 when Geode Capital Management, Llc sold 279 shares from its total ownership of 26608. The value for the sale was $23000. On the opposite side of that transaction from Geode Capital Management, Llc stood Vanguard Group Inc which added 3332 shares to its existing stake, bringing total stake held in UNH to 187898 shares. That transaction by Vanguard took place on June 30, 2017, the same day Susquehanna International Group, Llp purchased an additional 27696 shares in UNH to bring its total stake to 27696. Susquehanna’s stake was worth $24000 at the time of purchase. Institutional shareholders currently hold a 87.77% stake overall in UNH.

UnitedHealth Group Incorporated (NYSE:UNH) continues to be a formidable company. Current market cap is $190.17B and the stock has an EPS of $8.32. The P/E Ratio for UNH is 22.77. Over the course of the last year UNH has set a 52-week high of $200.76 while the corresponding low set was $133.03.